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Background: Palmitoyl ethanol amide (PEA) is an endogenously produced substance
showing anti-nociceptive effect through both receptor and non-receptor mediated effects
at the level of different cellular and tissue sites. This study showed the results of a
single blind study that was conducted to evaluate both the safety and the efficacy of
ultramicronized PEA (umPEA; 1,200 mg/day) for up 90 days in patients suffering of
Migraine with Aura (MA) treated with NSAIDs.
Methods: A total of 20 patients, 8 male (33–56-years, average 41.4 ± 7.8) and 12
female (19–61-years, average 38.5 ± 11.9) with MA were admitted to our observation
and diagnosed according to ICHD-3 criteria, they received umPEA (1,200 mg/day) in
combination with NSAIDs for up to 90 days. They were revaluated at 30, 60, and 90
days after treatment.
Results: umPEA administration induced a statistically significant and time dependent
pain relief. In particular, these effects were evident at 60 days (male P = 0.01189;
female P = <0.01) and they lasted until the end of the study (male P = 0.0066; female
P = 0.01473).
Conclusion: Although further studies are needed, our findings indicate that in patients
suffering of MA treatment with umPEA had good efficacy and safety which candidate this
compound as a therapeutic tool in pain migraine management.
Keywords: Migraine with aura, ultramicronized palmitoyl ethanol amide, pain, clinical trial, efficacy, safety
INTRODUCTION
Migraine is a common disabling primary headache disorder. It is the sixth highest cause of years
lost due to disability worldwide (1, 2) with high prevalence in young adults (3, 4). Migraine can
be classified in two major types: Migraine without aura characterized by headache with specific
features and associated symptoms and Migraine with aura (MA) characterized by the transient
focal neurological symptoms that usually precede or sometimes accompany the headache (5).
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In MA, the word “aura” denotes recurrent attacks of reversible
neurologic symptoms (e.g., visual, sensory, speech, motor, or
other central nervous symptoms) usually lasting few minutes.
Often the symptoms are unilateral, occurring on only one side
of the body or of the visual field; the aura is generally followed by
a headache (5).
Traditionally migraine treatment (with or without aura)
includes both prophylactic therapy, aimed at reducing the
frequency and severity of attacks, and acute therapy for halting
the progression of attacks. Unfortunately prophylactic therapy
rarely eliminates migraine (6), even though it is effective in
improving responsiveness to acute therapy, thus ameliorating
the level of disability. Triptans, non-steroidal anti-inflammatory
drugs (NSAIDs), and antiemetics represent the mainstay of
acute therapy (7, 8); however, in MA pain is less responsive to
triptans (9) and NSAIDs use is hampered by the development
of several adverse drug reactions (ADRs) (10, 11). Other
drugs such as antidepressants (duloxetine and amitriptyline)
and anticonvulsants (e.g., pregabalin and gabapentin) are also
able to induce pain relief through the modulation of synaptic
neurotransmitter levels leading to an improvement of quality
of life (12). However, like NSAIDs their use is limited by the
development of heavy side effects. Palmitoyl ethanol amide (PEA)
is an endogenous fatty acid amide widely distributed in different
tissues, including nervous tissues; it is synthesized on demand.
PEA is emerging as a novel therapeutic approach in pain and
inflammatory conditions (13). PEA has been reported to be
effective in animal models of chronic pain and inflammation as
well as in several clinical trials on various pain states (14–17).
However, to date no studies have been performed to evaluate the
role of PEA in the management of MA.
The aim of this study was to evaluate the efficacy and the safety
of chronic administration of ultramicronized PEA (um-PEA) in
patients with MA treated with NSAIDs.
METHODS
Study
We performed a prospective single-blind study from 2014 to
2015 in patients admitted to the Neurosurgery Division of “Mater
Domini” University Hospital in Catanzaro. The study protocol
was approved by the Local Ethics Committee (Catanzaro Centro
protocol number 235/2017), the enrolled patients signed the
written informed consent, and the work was conducted in
compliance with the Institutional Review Board/Human Subjects
Research Committee requirements. In order to exclude any risk
for the patients, both patients and physicians that evaluated the
patients knew the protocol and the group of treatment, while
physicians that evaluated the data were blinded to both protocol
and treatments.
Inclusion Criteria
Patients of both sexes>18 year-old and with 12months history of
MA andwith≥2 attacks/month in the least 12months, diagnosed
according to ICHD-3 criteria, and upon treatment with NSAIDs
(ibuprofen or diclofenac or nimesulide) were eligible for the
study.
Exclusion Criteria
Hypersensitivity to study drugs, progressive serious clinical
conditions (cancer, chronic hepatitis, human immunodeficiency
virus), neuropsychiatric diseases (e.g., psychosis and depression,
for the risk of low compliance), renal diseases (serum creatinine
concentration more than 1.2 times the upper limit of the normal
range according to the central laboratory reference values)
and liver dysfunction (serum alanine or aspartate transaminase
concentration more than 1.5 times the upper limit of normal
range according to the central laboratory reference values).
Patients with disorders capable of inducing the development
of aura (i.e., patent foramen ovale, ischaemic stroke, restless
legs syndrome, Parkinson’s disease, and psychiatric disorders),
patients with other diagnosis of headache (e.g., tension-type
headache) and patients who did not sign the informed consent
were also not considered eligible for the study.
Sample
The study sample includes 20 patients with MA, 8 male (33–
56-years, average 45.8 ± 7.8) and 12 female (19–61-years,
average 38.5 ± 11.9). All enrolled patients received a daily
treatment with umPEA (1,200 mg/day) for 90 days and used
a NSAID (ibuprofen, 600mg as requested and up to 1,200mg;
diclofenac sodium, 50mg as requested and up to 100mg/day, and
nimesulide, dosage 100mg as requested and up to 200mg/day) in
presence of acute headache pain.
Moreover, 20 patients with MA 10 male (35–59-years, average
42.4± 8.5) and 10 female (19–60-years, average 37.3± 10.6) were
also enrolled in this study as positive control-group receiving a
treatment with NSAIDs alone (ibuprofen, 600mg as requested
and up to 1,200mg; diclofenac sodium, 50mg as requested and
up to 100 mg/day, and nimesulide, dosage 100mg as requested
and up to 200 mg/day) in presence of acute headache pain.
In both groups, the follow-ups were performed at 30 (T1),
60 (T2), and 90 (T3) days after the starting from the time of
enrollment. Moreover, patients enrolled in these groups did not
receive any prophylaxis treatment for MA.
Assessment of Efficacy
In agreement with our previous study (18), a visual analogical
scale (VAS) was used to measure pain intensity before and after
the pharmacological treatment. A total VAS summary score was
calculated for each individual, adjusted, and reported on a 0–
100 scale. Lower scores were associated with less pain and better
function.
Assessment of Safety
Safety was assessed bymonitoring drug-drug interactions and the
incidence of adverse drug reactions (ADRs) which were assessed
for both severity and causality, in agreement with our previous
studies (19–22).
Efficacy End-Points
The primary efficacy end-point was defined as a statistically
significant difference (P < 0.05) in the improvement of pain
after um-PEA treatment measured during the three follow-up
visits (T1–T3) compared to admission (T0). Another primary
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efficacy end-point was the improvement of disability (evaluated
as the reduction of days with headache) after um-PEA treatment
measured during the follow-up visits (T1–T3) compared to
admission (T0). The secondary efficacy end-point was assessed
measuring the reduction of NSAIDs consumption (ibuprofen,
diclofenac sodium, or nimesuilde) in enrolled patients.
Safety End-Points
The primary safety end-point was defined as a statistically
significant difference (P < 0.05) in the development of any
adverse drug reaction. The secondary safety end-point was the
development of drug-drug interactions during the study.
Experimental Protocol
For ruling out secondary headache, patients underwent a
neurological examination, clinical biochemistry panel and
radiological evaluation (X-ray, computed tomography and
magnetic resonance imaging). Additionally a questionnaire was
administered in order to confirm the clinical diagnosis of
MA, according to ICHD-3 criteria (5), then a VAS was also
administered.
All patients enrolled in umPEA-group received a daily
treatment with umPEA (1,200 mg/day) for 90 days (end of the
study); during the study, an add-on treatment with NSAIDs
(ibuprofen, diclofenac sodium, or nimesuilde) was used for pain
relief during acute migraine attack (about 2 days for each attack).
Both umPEA and NSAIDs were bought by patients over the
counter from the open market.
Patients enrolled in control-group did not received umPEA
using ibuprofen or diclofenac sodium or nimesulide alone as
symptomatic treatment.
The follow-up visits were performed, in all groups, at 1 (T1),
2 (T2), and 3 (T3, end of the study) months after the first
administration of umPEA.
Statistical Analysis
A 17% difference in the VAS score was considered as minimal
clinical improvement threshold. In order to assess the clinically
relevant difference between each group, almost 20 subjects were
enrolled in each group (power >80%, alpha 0.05, two-tailed).
All data are expressed as mean ± standard deviation (SD). Data
were checked for normality using the Kolmogorove–Smirnov
test, while the Student’s t-test was used as post-hoc test. The
differences between multiple means was assessed using one-way
ANOVA and the Kruskal–Wallis test. A multivariate analysis
for age (continuous), sex (categorical), VAS score (continuous),
and ADRs (continuous) was also performed. The threshold of
statistical significance was set at P < 0.05. Statistical analysis was
performed using SPSS software version 21 (SPSS Inc., Chicago,
USA) was used.
RESULTS
Patients
In all enrolled patients (umPEA-group and control-group), the
laboratory parameters were in the normal range highlighting no
systemic diseases. Neurological examinations and radiological
TABLE 1 | Demographic characteristics of enrolled patients in umPEA-group at
the time of admission.
Sex Age
(years)
Attacks/month
(n)
VAS
(mm)
Days with pain
during each attack (n)
NSAID
F 19 2 8 4 Ibuprofen
F 24 2 9 2 Ibuprofen
F 48 4 9 3 Ibuprofen
F 61 4 7 4 Ibuprofen
F 38 3 7 3 Ibuprofen
F 48 4 8 3 Diclofenac
F 29 4 8 4 Ibuprofen
F 35 4 9 3 Nimesulide
F 49 3 8 3 Ibuprofen
F 30 3 7 4 Diclofenac
F 42 3 7 3 Ibuprofen
F 39 3 8 3 Ibuprofen
M 52 3 9 2 Diclofenac
M 38 4 9 4 Diclofenac
M 50 3 9 3 Nimesulide
M 56 4 7 4 Diclofenac
M 33 3 8 3 Ibuprofen
M 41 2 8 4 Ibuprofen
M 46 3 7 4 Nimesulide
M 50 3 8 3 Ibuprofen
Data are expressed as mean ± standard deviation.
findings confirmed the diagnosis of primary migraine excluding
secondary causes, while the questionnaire confirmed the
presence of aura.
All enrolled patients suffered from visual aura (with
phosphenes and teicopsies) and severe pain (VAS 7–10; umPEA-
group mean 8.0 ± 0.8: control-group mean: 8.05 ± 0.8,
P = 0.288) (Tables 1, 2).
As shown inTables 1, 2, at the time of enrollment (T0), in both
groups, the patients showed about 3 attacks/month (umPEA-
groupmean: 3.2± 0.7; control-groupmale 3.15± 0.6, P= 0.333)
and each pain attack lasted 2–4 days (umPEA-group mean 3.3 ±
0.7; control-group mean 3.2± 0.6, P = 0.27).
All enrolled patients (umPEA-group and control-group), did
not receive any prophylactic treatment for MA, but during
the acute headache attack used NSAIDs: ibuprofen (umPEA-
group: 12 patients; control group: 12 patients), diclofenac sodium
(umPEA-group: 5 patients; control group: 4 patients), and
nimesulide (umPEA-group: 3 patients; control group: 4 patients)
with no difference for sex or age (see Tables 1, 2).
As shown in Table 3, at T1 follow-up, umPEA treatment did
not significantly affect pain headache (P= 0.0675), in both sexes,
whereas a dramatic improvement in pain symptom was observed
at T2 patients, and this effect was maintained at the last follow up
(T3), irrespective to gender.
Moreover, at T3 both the days of pain and the number of
attacks/months were significantly reduced (primary end-point)
without difference for gender or age (T0: 3.1 ± 0.6; T3: 2.0 ±
1; P = 0.000, Table 3); a decrease in NSAIDs dosage was also
observed (primary end-point; Table 4).
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TABLE 2 | Demographic characteristics of enrolled patients in Control-group at
the time of admission.
Sex Age
(years)
Attacks/month
(n)
VAS
(mm)
Days with pain
during each attack (n)
NSAID
F 22 3 8 4 Ibuprofen
F 31 2 9 2 Ibuprofen
F 40 4 8 3 Ibuprofen
F 62 3 7 3 Ibuprofen
F 48 4 8 2 Diclofenac
F 32 4 8 3 Ibuprofen
F 31 4 9 3 Nimesulide
F 48 3 8 3 Ibuprofen
F 38 4 7 4 Ibuprofen
F 20 3 8 3 Nimesulide
M 55 3 9 3 Ibuprofen
M 35 3 9 4 Diclofenac
M 58 3 9 3 Nimesulide
M 43 3 8 4 Ibuprofen
M 56 3 7 3 Diclofenac
M 37 3 9 4 Ibuprofen
M 41 2 8 3 Ibuprofen
M 44 3 7 3 Nimesulide
M 28 3 7 4 Diclofenac
M 35 3 8 3 Ibuprofen
Data are expressed as mean ± standard deviation.
TABLE 3 | Effect of um-PEA on VAS score expressed by gender.
Sex T1 P-value T2 P-value T3 P-value
Male 7.5 ± 1.1 0.06976 6.5 ± 1.6 0.01189 5.3 ± 2.5 0.0066
Female 7.9 ± 0.8 1 7.3 ± 1.1 0.006412 6.3 ± 2.5 0.01473
Data are expressed as mean ± standard deviation. P-value for each follow-up (T1: 30
days; T2: 60 days; T3: 90 days) was calculated using the student t-test respect to T0
(admission) values.
In contrast, in control group, the treatment with NSAIDs
alone, even if induced a significant decrease in the intensity of
pain during each attack (P < 0.05), they failed to modify the pain
intensity during the recurrence of attacks (T0: 3.15± 0.6; T3: T0:
3.1± 0.6, P= 0.164) or their number/month (T0: 2.85± 0.4; T3:
2.75± 0.4, P = 0.08; Table 5).
In both groups clinical examination and laboratory assays
excluded the occurrence of major clinical event (see section
Methods), therefore we excluded the incidence of side effects
related to drug administration. All enrolled patients concluded
the study and no patients were missing to the follow-up.
DISCUSSION
Migraine is recognized as a neurogenic disorder associated
with secondary changes in brain perfusion (5). However, while
the neuroinflammation affecting cranial blood vessels and dura
sustains pain migraine in the early stages, the presence of
allodynia, hyperalgesia, and expansion of nociceptive fields
during migraine attacks is evocative of neuropathic pain, thus
implying the involvement of further mechanisms, such as
peripheral and central sensitizations (23, 24). As with other
neuropathic conditions the therapeutic management of migraine
is still a clinical challenge and several drugs have been proposed
(7, 25), since their use may be related with the development of
side effects (10, 25) or chronic migraine (26, 27).
In a previous case series, Hesselink (28) documented that the
administration of PEA 1,200mg/day in patients with neuropathic
pain was able to induce a significant pain decrease. In agreement,
we documented that the administration of topiramate and PEA
was able to decrease pain symptoms in patients with nummular
headache (15). Herein, we demonstrate for the first time that
umPEA administration to patients with MA (1,200 mg/day for
up 90 days) treated with common NSAIDs induced a significant
pain relief (evaluated considering the VAS score and the number
of attacks/month), irrespective to age or gender. These effects
were evident at 60 days after the beginning of umPEA-treatment
and lasted throughout the study. These results are in agreement
with previous reports showing the anti-nociceptive action of
umPEA in both preclinical models of neuropathic pain and with
clinical trials performed in a variety of pain states (14, 23).
The efficacy of PEA in reducing pain is related to its capability
to interfere with the inflammatory mechanism within the
nociceptive axis, allowing for a reduction of both peripheral and
central sensitization. PEA activity encompasses both neuronal
and non-neuronal cells (29, 30); the latter concerns the down-
regulation of mast-cell hyperactivity mediated by this compound
(31–33). Indeed, this cell population is often found in proximity
to sensory nerve endings and through the release of inflammatory
mediators and cytokines, stored in intracellular granules, they
can enhance the nociceptive signal. Remarkably, mast-cells also
colonize the spinal dura, the thalamus and the dura mater (31–
33).
Moreover, in our study we also documented that patients
treated with umPEA reduced the NSAIDs consumption, while
this was not recorded in control-group.
In this frame, PEA might represent a useful therapeutic
approach for migraine, as meningeal nociceptors can be activated
locally through a neuro-immune interplay with resident mast
cells populating the dura mater (34).
Previous studies reported that treatment with PEA does not
cause adverse events or drug interactions and it doesn’t induce
pharmacological tolerance (16, 35–37). Our data demonstrate
that um-PEA chronically administered for 90 days and
occasionally added on to NSAIDs significantly reduces the score
of pain intensity, the number of attacks/month, and the days of
pain during each attack irrespective to age and gender, suggesting
a synergic effect of these compounds.
This synergic effect is possibly related to the different
mechanisms of action of the drugs used. In fact, PEA has
dose-dependent anti-inflammatory and analgesic effects related
to the modulation of mast-cell and microglia and is able
to reduce pain, to preserve peripheral nerve morphology, to
reduce endoneural edema, the recruitment and activation of
mast cells, and the production of pro-inflammatory mediators
(38–40). On the other hand NSAIDs have a dose-dependent
anti-inflammatory and analgesic effect related to the inhibition
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TABLE 4 | Effect of 90 days um-PEA in enrolled patients.
Attacks/month
Male
Attacks/month
Female
Days of pain/attack
male
Days of pain/attack
female
Ibuprofen
(mg/day)
Diclofenac
(mg/day)
Nimesulide
(mg/day)
T0 2.9 ± 0.4 3.3 ± 0.8 2.85 ± 0.4 2.22 ± 0.6 1200 100 200
T3 1.5 ± 0.5 2.4 ± 1.1 1.5 ± 0.6 1.1 ± 0.3 600 50 100
P-value 0.000 0.005 0.000 0.000 0.000 0.000 0.000
P-value was calculated using the student t-test respect to T0 (admission) values.
TABLE 5 | ANOVA test analysis between case and control groups at admission
(T0) and at the end of the study (T3).
F-value P F statistic
ATTACKS/MONTH
T0 0.06 0.80 4.09
T3 16.93 0.000201 4.09
VAS
T0 0.04 0.84 4.09
T3 12.91 0.000925 4.09
DAYS OF PAIN
T0 0.25 0.62 4.09
T3 112.44 6.53E-13 4.09
At T3 we documented a significant difference between control and umPEA- treated group
in all variable evaluated (P < 0.01).
of prostaglandins; however their use must be monitored,
particularly in elderly patients, for potential gastrointestinal and
hepatic risks, cardiovascular and renal side effects, and drug-drug
interactions (41–43).
In our study, we did not record the occurrence of any major
ADRs related to NSAIDs administration and this could be related
to the short time of treatment (occasional use for 2 days) and
also to the low dosage used. In particular, the treatment with
um-PEA allowed a decrease in NSAIDs dosage in all patients
suggesting that this combination may be useful to reduce the
toxicity in patients underwent to polytherapy. The data also
confirm the safety of treatment with um-PEA. Indeed, no adverse
drug reactions or interactions were recorded during the study
highlighting an optimal um-PEA pharmacological profile and the
adherence with the umPEA regimen was good with a rate of
100%.
Finally, even without having performed a pharmacoeconomic
analysis, these data suggest that this combination may help to
reduce the cost of migraine, including drugs, hospitalization, and
toxicity.
However, this study had some major limitations represented
by the method used (single blind), the limited sample
size and the brief duration of follow-up, so we defined
this study as a pilot study and other clinical trials in
a large population must be performed to confirm these
data.
Although PEA is not reported in guidelines of migraine
treatment, in our study the chronic administration of um-PEA
to patients with MA in combination with NSAIDs, induced
a significant pain relief allowing the reduction of the NSAID
dosage. Remarkably, the compound was also able to reduce the
number of migraine attacks. No major adverse drug reactions
or interactions were recorded during the study. These data,
compatibly with the design of the trial, are suggestive of an
optimal pharmacological profile forum-PEA.
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